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Summary 
Cerebral deposition of p-amyloid protein is a pathologi- 
cal feature central to Alzheimer's disease. Production 
of J]-amyloid by proteolytic processing of the p-amyloid 
precursor protein (pAPP) is a critical initial step in J~-amy- 
Ioidogenesis. We use an inhibitor of pAPP processing 
to block p-amyloid peptide formation. Application of 
the inhibitor to cultured cells results in an accumula- 
tion of proteolytic intermediates of pAPP, enabling a 
precursor-product relationship between pAPP car- 
boxy-terminal fragments and ~-amyloid peptides to be 
demonstrated directly. In the presence of inhibitor, 
these amyloidogenic carboxy.-terminal fragments can 
be degraded to nonamyloidogenic products. The ca- 
tabolism of pAPP carboxy-terminal intermediates and 
the formation of p-amyloid peptides are likely to in- 
volve an early endosomal compartment as the subcel- 
lular site of processing. 
Introduction 
Metabolism of 13-amyloid precursor protein (~APP) in AIz- 
heimer's disease and Down's syndrome, as well as some 
elderly normal individuals, leac:s to the production and 
accumulation of a 4 kDa proteolytic leavage product, the 
13-amyloid peptide. Two major pathways of ~APP pro- 
cessing have been identified that are implicated in the 
formation of ~-amyloid. One pathway involves proteolytic 
cleavages that result in the secretion of truncated I3APP 
and the concomitant formation of 8-12 kDa carboxy- 
terminal remnants (Caporaso e~ al., 1992; Golde et al., 
1992; Estus et al., 1992; Haass et al., 1992a). The bulk 
of these carboxy-terminal secretion products are nonamy- 
Ioidogenic, since secretory cleavage most frequently oc- 
curs within the 13-amyloid omain situated in the carboxy- 
terminal region of the precursor protein (Esch et al., 1990). 
Only a small proportion of secretory cleavage products 
appears to be potentially amyloidogenic (Seubert et al., 
1993). Evidence exists supporting both intracellular (Sam- 
bamurti et al., 1992; De Strooper et al., 1993; Kuentzel 
et al., 1993) and membrane surface sites (Sisodia, 1992; 
Haass et al., 1992a; Kuentzel et al., 1993) for the constitu- 
tive secretory cleavage process, and it appears that multi- 
ple locales of cleavage exist along the intracellular secre- 
tory pathway of ~APP. 
A second processing pathway involving the endosomal/ 
lysosomal system has also been suggested as the site of 
formation for amyloidogenic 13APP carboxy-terminal frag- 
ment and J3-amyloid. This pathway was identified through 
observations with cultured mammalian cells treated with 
inhibitors of lysosomal activity such as chloroquine, E64, 
or leupeptin. These compounds promote the accumula- 
tion of a number of ~APP carboxy-terminal derivatives, 
including larger potentially amyloidogenic fragments (Ca- 
poraso et al., 1992; Haass et al., 1992a; Golde et al., 1992; 
Hayashi et al., 1992; Busciglio et al., 1993; Siman et al., 
1993). Further evidence for the participation of lysosomes 
in the generation of amyloidogenic processing products 
of J3APP comes from the presence of such fragments in 
crude lysosomal preparations from cultured cells (Haass 
et al., 1992a) and the association of active lysosomal 
enzymes with ~-amyloid eposits in Alzheimer's disease 
brain (Cataldo and Nixon, 1990). 
Although lysosomal inhibitors have been shown to 
cause an accumulation of ~APP carboxy-terminal proteo- 
lytic cleavage intermediates, including those that could be 
processed further to yield J3-amyloid peptide, these inhibi- 
tore have little or no effect on the formation of the 4 kDa 
J3-amyloid peptide. Specifically, treatment of cell cultures 
with leupeptin or E64 does not block the formation of l~-amy- 
Ioid (Shoji et al., 1992; Haass et al., 1993; Busciglio et 
al., 1993). Short periods of treatment with chloroquine or 
NH4CI result in modest effects on ~-amyloid production 
(Busciglio et al., 1993); however, extended treatments are 
inhibitory (Shoji et al., 1992; Haass et al., 1993). These 
results indicate that the lysosome may not be participating 
directly in the processing of ~APP to ~-amyloid peptide. 
Additional pharmacological studies employing inhibitors 
of Golgi processing such as monensin and brefeldin A 
were found to block the formation of ~-amyloid, suggesting 
that the 4 kDa peptide is generated in the secretory path- 
way distal to the endopla:~mic reticulum and early Golgi 
(Busciglio et al., 1993; Haass et al., 1993). These data 
imply that there may be multiple subcellular sites of I3APP 
processing giving rise to a collection of amyloidogenic ar- 
boxy-terminal fragments, only a subset of which may be 
precursors of 13-amyloid peptide. 
An inhibitor that acts directly on the processing of B-amy- 
Ioid would be useful in resolving which ~APP carboxy- 
terminal fragments are the authentic proteolytic precursors 
of ~-amyloid, as well as in defining the subcellular locale(s) 
involved in 13APP catabolism and ~-amyloidogenesis. Here 
we describe the application of an inhibitor capable of 
blocking 13-amyloid formation in vitro to address these issues. 
Results 
Inhibition of p-Amyloid Processing 
by the MDL 28170 Inhibitor 
Cultured mammalian cells have been reported to produce 
and secrete 13-amyloid peptides that include an intact 4 
kDa ~-amyloid peptide identical to that purified from AIz- 
heimer's disease brain and an amino-terminally truncated 
3 kDa peptide derived from the secretory cleavage of 
~APP (Haass et al., 1992b; Shoji et al., 1992; Busciglio 
et al., 1993). Therefore, we utilized Chinese hamster ovary 
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Figure 1. EffectsofDrugson ~APPCarboxy-TerminalFragmentsand 
on 13-Amyloid Peptides 
BC1 antiserum was used to immunoprecipitate I~APP carboxy-terminal 
fragments from cell lysates (A), and BA2 antiserum was used to immu- 
noprecipitate I~-amyloid peptides present in media (B). Lane 1, no 
drug treatment; lane 2, 200 I~M MDL 28170 inhibitor; lane 3,200 I~M 
leupeptin; lane 4, 200 I~M E64; lane 5, 100 p.M chloroquine; lane 6, 30 
mM NH4CI; lane 7, 30 mM NH,-acetate; lane 8, 30 mM methylamine. 
Molecular weight markers (M) are indicated. The four major 13APP 
carboxy-terminal fragments, ranging in molecular weight from 8.0 to 
12.0 kDa, that accumulate from MDL inhibitor t eatment are identified 
in (A), and the 4 and 3 kDa 13-amyloid peptides are indicated in (B). 
MDL 28170 structure is in ((3). Treatment with each drug was for 4 hr 
and was simultaneous with [~S]methionine/cysteine lab ling. 
(CHO) cells stably transfected with the 695 amino acid 
isoform of 13APP as a source of 13-amyloid peptides and 
a system for study. A clonal line from the CHO cell transfec- 
tion (CP-6) was metabolically labeled with [35S]methionine/ 
cysteine for 4 hr in the absence and presence of various 
drugs. The set of compounds applied included: inhibitors 
of lysosomal cysteine proteinases, leupeptin and E64; 
acidotrophic agents that neutralize lysosomes and other 
acidic compartments such as endosomes and late and 
medial Golgi compartments, chloroquine, NH4-acetate, 
NH,CI, and methylamine; and the calpain proteinase 
inhibitor, MDL 28170 (Mehdi et al., 1988; Mehdi, 1991). 
The chemical structure of the MDL inhibitor, an amino- 
terminal blocked dipeptide aldehyde, is displayed in Fig- 
ure 1C. After the labeling period, cells and conditioned 
media were harvested. Cell iysates were prepared, I~APP 
carboxy-terminal fragments were immunoprecipitated with 
an antiserum directed to the cytoplasmic domain of ~APP 
(BC1), and the precipitates were analyzed by polyacryi- 
amide gel electrophoresis using a Tris-Tricine buffer sys- 
tem. Conditioned media were immunoprecipitated with an 
antiserum raised to synthetic 13-amyloid 1-40 peptide, 
BA2. This latter antiserum has been fully characterized 
with respect to its specificity for 13-amyloid and the epitope 
recognized within 13-amyloid. Synthetic ~-amyloid peptide 
representing residues 1-40 can successfully compete the 
immunoprecipitation of [35S]methionine-labeled 4 and 3 
kDa I~-amyloid peptides released from cultu red cells (data 
not shown). The 13-amyloid peptides were analyzed by 
16.5% Tris-Tricine polyacrylamide gel electrophoresis. 
The effect of each compound on 13APP carboxy-terminal 
fragment and p-amyloid peptide production is shown in 
Figure 1. Leupeptin and E64 had no effect on the levels 
of carboxy-terminal fragments generated during the 4 hr 
labeling period, and neither drug reduced levels of 4 and 
3 kDa I~-amyloid peptides as compared with the untreated 
culture. Treatment with NH4CI, NH4-acetate, and methyl- 
amine each resulted in an increase in an 8 kDa 13APP 
carboxy-terminal fragment, as well as a modest reduction 
of I~-amyioid peptides. Chloroquine gave similar results to 
NH,CI, NH4-acetate, and methylamine. In contrast, the 
MDL inhibitor completely inhibited the formation of both 
4 and 3 kDa I~-amyloid peptides. In addition, the MDL inhib- 
itor caused an accumulation of four prominent 13APP car- 
boxy-terminal fragments ranging in molecular weights 
from 8.0 to 12.0 kDa. Several minor larger fragments were 
also enhanced by treatment with the MDL inhibitor. 
Characterization of pAPP Carboxy-Terminal 
Fragments 
The four predominant J3APP carboxyl termini that accumu- 
lated as a result of inhibition of I~APP processing by the 
MDL inhibitor were each characterized by radiosequenc- 
ing. CP-6 cells were metabolically labeled with either 
[3H]alanine or [3H]phenylalanine in the presence of the 
M DL 28170 inhibitor, after which these 8.0-12.0 kDa 13APP 
carboxy-terminal fragments were separated by electro- 
phoresis on 16.5% Tris-Tricine polyacrylamide gels, iso- 
lated, and microsequenced. The fastest migrating frag- 
ment, with an apparent molecular weight of 8.0 kDa, has 
an amino terminus beginning with leucine-17 of the 
15-amyioid peptide. We observed [3H]alanine in cycles 5 
and 14, and [3H]phenylalanine in cycles 3 and 4 (Figure 
2A). The next fastest migrating 13APP fragment of 8.8 kDa 
was found to initiate with tyrosine-10 of 13-amyloid, since 
the radio-amino acid sequencing yielded [3H]phenylalan- 
ine at cycles 9 and 10 and [~H]alanine at cycles 11 and 
20, as well as at cycles 5 and 14 (Figure 2B). The [3H]alan- 
ine seen in cycles 5 and 14 is likely to be due to contamina- 
tion from the very abundant adjacent 8.0 kDa fragment. 
Sequencing of the third and 10.0 kDa ~APP carboxy- 
terminal fragment revealed that this fragment possesses 
the mature amino terminus of 13-amyloid commencing with 
aspartate-l. Upon microsequencing of this fragment, 
[3H]phenylalanine and [3H]alanine were observed in cycles 
4 and 2, respectively (Figure 2C). The largest I~APP car- 
boxy-terminal fragment of the set was calculated at an 
apparent molecular weight of 12.0 kDa. Sequencing of 
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Figure 2. Radiosequence Analysis of ~SAPP 
Carboxy-Terminal Fragments Accumulating 
from Inhibition of ~-Amyloid Processing by the 
MDL 28170 Inhibitor 
(A) Analysis of the 8.0 kDa fragment using 
[3H]phenylalanine and [3H]alanine. 
(B) Analysis of the 8.8 kDa fragment using 
[3H]phenylalanine and [SH]analine. Asterisks 
indicate contaminating radioactive peaks from 
the 8.0 kDa fragment. 
(C) Analysis of the 10.0 kDa fragment using 
[3H]phenylanaline and [SH]alanine. 
(D) Analysis of the 12.0 kDa fragment using 
pH]phenylanaline. 
(E) Partial i~APP amino acid sequence illustrat- 
ing cleavage sites yielding the 8.0, 8.8, 10.0, 
and 12.0 kDa fragments (arrows). The first 
residue of the 4 kDa ~-amyloid s also indi- 
cated (1). 
this 12.0 kDa fragment gave a peak of [3H]phenylalanine 
at cycle 16, indicating that the amino terminus of this 
fragment is extended by 12 residues from the mature 
13-amyloid amino terminus (or at asparagine-585 of the 
~APP(395 isoform sequence). Sequencing results for the 
12.0 kDa fragment labeled with [3H]alanine were inconclu- 
sive owing to the low yield of this proteolytic product. In 
support of these data, when this same set of four 6APP 
carboxyl termini was prepared unlabeled (employing a dif- 
ferent ~APP expression system and cell background), and 
when the amino-terminal sequence of each fragment was 
determined directly, the sequences obtained were in 
agreement with these results (data not shown). Both the 
10.0 and 12.0 kDa fragments qualify as potential precur- 
sors to the 4 kDa ~-amyloid peptide. 
Identification of Proteolytic Precursors 
to I~-Amyloid Peptides 
To examine the possible precursor-product relationship 
between these ~APP carboxy-terminal fragments and the 
~-amyloid peptides, we took advantage of the fact that the 
effects of the MDL 28170 inhibitor can be reversed by 
simply washing the cell monolayers. CP-6 cell cultures 
were treated with the MDL inhibitor for 1 hr, during which 
time they were also metabolically !abeled with [3sS]methio- 
nine/cysteine. After the inhibitor treatment and labeling 
period, the cells were washed and placed in medium lack- 
ing radioactivity and inhibitor. Cells and su pernatants were 
harvested at 0, 30, 60, 120, and 180 min after removal of 
the inhibitor and isotope, then analyzed for 13APP carboxy- 
terminal fragments and 13-amyloid peptides. The results 
from this inhibitor wash-out experiment are presented in 
Figure 3. At the commencement of the chase period, accu- 
mulation of the 8.0-12.0 kDa 13APP carboxyl termini and 
inhibition of 13-amyloid peptides were evident. However, 
30 min after removal of the MDL inhibitor, there was a 
loss of carboxy-terminal fragments with a concomitant for- 
mation of the 4 and 3 kDa 13-amyloid peptides. By 120 min 
after removal of inhibitor, only trace amounts of carboxyl 
termini remained, and levels of I~-amyloid peptide were 
nearly equivalent o that produced by control cells which 
were not treated with the MDL inhibitor but were pulse 
labeled for 1 hr and then chased for 180 min. At 180 min, 
control- and M DL inhibitor-treated samples were not iden- 
tical in that processing of drug-treated carboxy-terminal 
fragments occurred faster. The reason for this temporal 
discrepancy is not clear. 
Degradation of p-Amyloid Proteolytic Precursors 
We were interested in the fate of the 13APP carboxy- 
terminal fragments that accumulate upon MDL inhibition 
of 13-amyloid peptide processing, in particular, whether 
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Figure 3. Demonstration fPrecursor-Product Relationship between 
[BAPP Carboxy-Terminal Fragments and I)-Amyloid Peptides using 
MDL Inhibitor Wash-Out 
(A) [BAPP carboxy-terminal fragments immunoprecipitated with BC1 
antiserum from cell lysates; (B) J~-Amyloid peptides immunoprecipi- 
tated from conditioned media with BA2 antiserum. Cellular protein was 
metabolically labeled with [~S]methionine/cysteine for 60 rain in the 
presence of 200 I~M MDL 28170 inhibitor. After labeling, cells were 
washed free of label and inhibitor and then chased in isotope- and 
inhibitor-free medium. Samples were harvested at the chase times 
indicated (0-180 min), immunoprecipitated, and analyzed as de- 
scribed in the text. A sample (CON) that was labeled for 60 min and 
chased for 180 min in the absence of the MDL 28170 inhibitor served 
as a control. Molecular weight standards (M) are indicated. 
these fragments can be alternatively degraded in the con- 
t inued presence of the MDL 28170 inhibitor. To examine 
this possibility, we employed two experimental  paradigms; 
first, a radiolabel pulse for protein synthesis fol lowed by 
a nonradioactive chase period to follow protein turnover, 
and second, continuous protein radiolabeling to observe 
steady-state protein levels. For the radiolabel pulse-chase 
experiments, CP-6 cells were pulse labeled with [3~S]me- 
thionine/cysteine for 1 hr in the presence or absence of the 
MDL inhibitor, after which the cells were placed in medium 
lacking radiolabel, again in either the presence or absence 
of the MDL inhibitor. Samples were harvested at 1, 2, 4, 6, 
8, and 10 hr into the chase. Cell lysates were immunopre- 
cipitated with BC1 antiserum to characterize I~APP car- 
boxy-terminal fragments; media were immunoprecipitated 
with BA2 antiserum to assay 13-amyloid peptides. As ex- 
pected, in the presence of the MDL inhibitor, carboxy- 
terminal fragments dramatical ly accumulated ( -50- fo ld  
over levels in untreated cultures) during the first 2 hr of the 
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Figure 4. Effect of MDL Inhibition of 13APP Carboxy-Terminal Frag- 
ments and 13-Amyloid Peptides in a Pulse-Chase Experimental Format 
(A and C) Accumulation and degradation of pulse-labeled I)APP car- 
boxy-terminal fragments over 10 hr (A) and 24 hr (C) chase periods. 
([A] was intentionally overexposed to emphasize minor degradation 
fragments.) 
(B) Inhibition of pulse-labeled [B-amyloid peptides by the MDL 28170 
inhibitor over a 10 hr chase period. The (+) and (-) denote the presence 
and absence of 200 I~M MDL 28170 inhibitor, respectively. Cellular 
protein was metabolically labeled with [~S]methionine/cysteine for 1 
hr, after which isotope was removed and cells were placed in isotope- 
free medium (time 0 of the chase period). A graphical representation 
of the data in (C) is presented in (D). Open and closed circles indicate 
addition or absence, respectively, of the MDL 28170 inhibitor. 
13-Amyloid Processing 
655 
0 
r - - [  F - -  
m MDL + 
2 
,t- 
6 8 
l r - -  P F - -  
- + + 
24 hr. 
l - -  
+ 
] 
M kDa 
29 
18 
14 
0 2 
f - - I  F - -  
B MDL + 
6 8 
+ - ~ - + 
24 hr. 
q 
+ M kDa 
18 
14 
Figure 5. Effect of the MDL 28170 Inqibitor n ~APP Carboxy-Ter- 
minal Fragments and ~-Amyloid Peptides in a Continuous Labeling 
Experimental Format 
I3APP carboxy-terminal fragments (A) and J3-amyloid peptides (B) pro- 
duced upon continuous labeling with pS]methionine/cysteine in either 
the absence (-) or the presence (+) of 200 ~M MDL inhibitor. Samples 
were harvested at the times indicated over a 24 hr labeling period. 
chase period, after which time the levels of the fragments 
decreased. By 10 hr, an 8-fold reduction from initial accu- 
mulated levels could be determined (Figure 4A). New, 
smaller (5-7.5 kDa) immunoprecipitable fragments ap- 
peared at4 hr into the chase period and were present at all 
later time points. As the J3APP carboxy-terminal fragments 
were gradually depleted over the chase period, complete 
inhibition of 13-amyloid peptide formation was sustained 
throughout the entire 10 hr chase period, indicating that the 
degradation of MDL inhibitor-induced carboxy-terminal frag- 
ment accumulation was to nonamyloidogenic products 
(Figure 4B). When this experiment was repeated and 
the fate of 13APP carboxy-terminal fragments was followed 
out to 24 hr, only a small residual amount (13%) of 13APP 
fragments remained after 24 hr (Figures 4C and 4D). Con- 
tinuous labeling experiments carried out in the presence 
or absence of the MDL inhibitor evealed a nearly complete 
inhibition of ~-amyloid peptides at all time points (Figure 
5B). Also, continuous labeling after 2 hr produced a com- 
posite of immunoprecipitated proteins reflecting the accu- 
mulation of amyloidogenic arboxyl termini, as well as the 
novel 5-7.5 kDa catabolic fragments noted above in the 
pulse-chase fragment turnover experiments (Figure 5A). 
When these 5-7.5 kDa J~APP carboxy-terminal derivatives 
were analyzed by immunoprecipitation with several 
~-amyloid peptide antisera, including BA2, none reacted, 
indicating that they were degraded to non-l~-amyloid pep- 
tide products. 
Because the 13APP proteolytic intermediates that accu- 
mulated due to inhibition of 13-amyloid processing by the 
MDL 28170 inhibitor were eventually degraded to nonamy- 
Ioidogenic products, we determined the effect of various 
drugs capable of inhibiting different subcellular compart- 
ments, to identify the locale where these fragments are 
metabolized. All of the following experiments were identi- 
cal in design. A pulse-chase format was followed in which 
CP-6 cell cultures were radiolabeled with [3~S]methionine/ 
cysteine for 1 hr, after which label was removed and the 
cultures were incubated for chase periods of 0, 4, 8, 12, 
and 24 hr. The MDL inhibitor was present in all cultures 
during the entire pulse-chase period. Multiple pairs of CP-6 
cell cultures were prepared in this fashion. To one set of 
cultures, a second inhibitor was added at the initiation of 
the chase period, in addition to the MDL 28170 inhibitor; 
the other set was treated with only MDL inhibitor. The 
inhibitors assayed in this experiment included: two inhibi- 
tors of lysosomal proteinases, leupeptin and E64; two 
acidotropic agents, chloroquine and NH4CI, which neutral- 
ize lysosomes and other acidic compartments uch as 
endosomes and the trans-Golgi network; monensin, a car- 
boxylic ionophore that blocks protein processing and 
transport within the distal Golgi and that also disrupts en- 
dosome/lysosome function; and brefeldin A, which blocks 
protein transport by causing the resorption of the Golgi 
into the endoplasmic reticutum. 
In this series of experiments, we found that he thiol 
proteinase inhibitors, leupeptin and E64 (Figures 6B and 
6C), had no effect on MDL inhibitor-induced I3APP car- 
boxy-terminal fragment catabolism compared with control 
cultures (Figures 6A and 6E). Similarly, brefeldin A did not 
prevent the degradation of these fragments (Figure 6D). 
In contrast, chloroquine and NH4CI both retarded the clear- 
ance of ~APP termini (Figures 6F and 6G), while monensin 
prevented the degradation of these fragments (Figure 6H). 
The catabolism of the 10.0 and 12.0 kDa amyloidogenic 
~APP fragments was inhibited by monensin, and these 
fragments persisted throughout he 24 hr chase period. 
In a different experiment, accumulated pulse-labeled car- 
boxy-terminal precursors, when washed free of the MDL 
inhibitor, were not processed into J3-amyloid peptides when 
monensin was present (data not shown), suggesting that 
the compartments involved in processing the carboxyl ter- 
mini of ~-amyloid peptides and the degradation of I~APP 
fragments are the same. We also utilized reduced temper- 
atures to halt 6APP processing at the endoplasmic reticu- 
lum (15°C) and at the trans-Golgi network (23°C) in the 
presence and absence of the MDL inhibitor, in the pres- 
ence of inhibitor, carboxy-terminal fragment accumulation 
occurred only at 37°C. The formation of ~-amyloid pep- 
tides was seen only in the absence of inhibitor at 37°C 
and not at the lower temperatures (data not shown). These 
data, together with those derived from chemical inhibition 
of protein transport, indicate that a post-Golgi, pre-lysosomal 
compartment is involved in "y-secretase processing of 13APP 
carboxy-terminal fragments to ~-amyloid. 
Neuron 
656 
A 0 4 8 12 24 B 
CON LEU 
C 0 4 8 12 24 D 
E64 BFA 
E 0 4 8 12 24 F 
CON CLQ 
0 4 8 12 24 hrs 
0 4 8 12 24 
0 4 8 12 24 
Figure 6. Effects of Drugs on the Degradation 
of 13APP Carboxy-Terminal Fragments Accumu- 
lating from Inhibition of ~-Amyloid Processing by 
the MDL Inhibitor 
Cells were pulse labeled with [3SS]methionine/ 
cysteine for 1 hr in the presence of 200 I~M MDL 
28170 inhibitor. At the start of the 24 hr chase 
period, a second inhibitor was added tothe me- 
dia containing the MDL 28170 inhibitor. Samples 
were taken for analysis at the times shown (0, 
4, 8, 12, and 24 hr). (A) MDL inhibitor only (CON); 
(B) MDL inhibitor plus 200 p.M leupeptin (LEU); 
(C) MDL inhibitor plus 200 p.M E64 (E64); (D) 
MDL inhibitor plus 10 p.M brefeldin A (BFA); (E) 
MDL inhibitor only (CON); (F) MDL inhibitor plus 
100 #.M chloroquine (CLQ); (G) MDL inhibitor 
plus 30 mM NH4CI (NH,CI); (H) MDL inhibitor 
plus 10 p.M monensin (MON). All control samples 
were approximately identical; onlytwo are shown 
for space purposes, The migration ofinternal mo- 
lecular weight standards is indicated. 
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Discuss ion 
The finding that 13-amyloid peptide is produced by normal 
physiological processes and is released by cultured cells 
(Shoji et al., 1992; Haass et al., 1992b; Busciglio et al., 
1993) has provided a system to enhance our understand- 
ing of the molecular mechanisms leading to the formation 
of this 4 kDa derivative of 15APP that is deposited in AIzhei- 
mer's disease. The location of the I~-amyloid sequence 
within I~APP dictates the involvement of proteolytic leav- 
age events in the formation of this peptide. Two pathways 
have been proposed as potential candidates for 13-amyloid 
production, the secretory and lysosomal pathways. Amy- 
Ioidogenic fragments of I~APP have been identified as pro- 
teolytic processing intermediates of both pathways (Seu- 
bert et al., 1993; Haass et al., 1992a; Estus et al., 1992; 
Golde et al., 1992; Siman et al., 1993). However, it has not 
been directly demonstrated that any naturally occurring 
I~APP amyloidogenic processing products are authentic 
precursors of I~-amyloid peptide. Results from pharmaco- 
logical studies suggest that 13-amyloid peptide is gener- 
ated within the cellular secretory pathway, since the gene- 
sis of the peptide is sensitive to agents that block protein 
transport hrough the secretory pathway (Busciglio et al., 
1993; Haass et al., 1993). However, it does not appear 
that the proteolytic leavage that produces secreted 13APP 
is involved in I~-amyloidogenesis. Agents that stimulate 
protein kinase C and enhance secretion of 13APP, such 
as phorbol esters, reduce levels of the 4 kDa 13-amyloid 
peptide while simultaneously increasing levels of the 3 
kDa amyloid peptide 13APP secretion by-product (Bux- 
baum et al., 1993; Hung et al., 1993; Gabuzda et al., 1993). 
Presumably, for a given amount of I~APP substrate, en- 
hancing I~APP secretion, and thus the 3 kDa peptide, de- 
pletes I~APP substrate available for 4 kDa I~-amyloid pro- 
duction. 
Furthermore, lysosomal proteolysis not responsible 
for the formation of the 13-amyloid peptides, since inhibitors 
of lysosomal proteinases, E64 and leupeptin, do not block 
their formation (Shoji et ai., 1992; Haass et al., 1993; Bus- 
ciglio et al., 1993; results herein). However, 13-amyloid pep- 
tide genesis is sensitive to acidotrophic agents, such as 
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NH4CI and chloroquine, indicating that a weakly acidic 
subcellular compartment is involved (Shoji et al., 1992; 
Haass et al., 1993; Busciglio et al., 1993; results herein). 
To define better the events leading to ~-amyloid peptide 
formation, we have applied an inhibitor, MDL 28170 (Mehdi, 
1991), that blocks processing of ~APP to I~-amyloid peptides. 
Application of the MDL inhibitor to cultured mammalian cells 
was found to inhibit the production of both the 4 and 3 
kDa ~-amyloid peptides, while concomitantly producing 
an accumulation of 13APP ca~'boxy-terminal fragments 
ranging in size from 8.0 to 12.0 kDa. The MDL 28170 
inhibitor blocks the processing of these 6APP fragments 
by preventing the cleavage that produces the carboxyl 
termini of the 13-amyloid peptides. In other words, the MDL 
inhibitor appears to inhibit ¥-secretase activity. The MDL 
28170 inhibitor as described by Mehdi (1988, 1991) is a 
calpain proteinase inhibitor; however, no direct evidence 
exists that ~,-secretase isa thiol proteinase, or is a calcium- 
activated thiol proteinase. 
A direct precursor-product relationship between the 
8.0-12.0 kDa carboxyl termini of 13APP and the 4 and 3 
kDa I~-amyloid peptides was demonstrated. Removal of 
the MDL 28170 inhibitor from the cells resulted in the grad- 
ual disappearance of these 13APP fragments, with a recip- 
rocal production of both the 4 and 3 kDa ~-amyloid pep- 
tides. Additional supporting evidence for the precursor ole 
of these 13APP fragments was obtained from sequence 
analysis. The predominant 8.0 kDa fragment was found 
to have an amino terminus consistent with the major cleav- 
age site used for 13APP secretion, i.e., leucine-17 of the 
13-amyloid peptide (Esch et al., 1990; Anderson et al., 1991 ; 
Zhong et al., 1994). Therefore, this 8.0 kDa carboxy- 
terminal ~APP fragment is the precursor to the 3 kDa pep- 
tide, since Busciglio et al. (1993) and Haass et al. (1992b) 
characterized the amino term in us of a major 3 kDa species 
as initiating with leucine-17. Other 3 kDa peptides with 
truncated amino termini have also been described (Bus- 
ciglio et al., 1993; Haass et al., "!992b). The amino termi- 
nus of a minor 8.8 kDa carboxy-terminal fragment that 
accumulates with MDL 28170 inhibitor treatment does 
not correspond to any of the reported 3 kDa peptide se- 
quences. This fragment would produce a peptide bearing 
an amino terminus of tyrosine-10. The amino-terminal het- 
erogeneity observed by sequence analysis of the 3 kDa 
secreted products may reflect heterogeneity in the proteo- 
lytic cleavage leading to ~APP secretion, as has been 
reported (Zhong et al., 1994), and/or might result from 
exoaminopeptidase activity or additional proteolytic pro- 
cessing following an initial set o'I cleavages. 
The amino terminus determined for a 10.0 kDa carboxy- 
terminal precursor fragment corresponds to the mature 
amino terminus of J3-amyloid, aspartate-l. The amino ter- 
minus of this fragment is in agreement with that reported 
for the major 4 kDa amyloidogenic peptide produced in 
vitro and in vivo (Haass et al., 1992b; Shoji et al., 1992; 
Seubert et al., 1992). Additional 4 kDa species have also 
been described that reflect amino-terminal extensions 
(Busciglio et al., 1993) or truncations (Haass et al., 1993). 
The presence of 13-amyloid peptides with amino-terminal 
extensions are compatible with the larger 12.0 kDa amy- 
Ioidogenic carboxy-terminal IBAPP fragment hat accumu- 
lates when 13-amyloid processing is inhibited. 
The coinhibition of the 4 and 3 kDa peptides by the MDL 
28170 inhibitor suggests that a common cellular pro- 
cessing compartment is used for the carboxy-terminal pro- 
cessing that generates the two peptides. The most likely 
subcellular site(s) is the trans-Golgi network or early endo- 
some. Experiments involving the inhibitor brefeldin A re- 
veal that transport of 13APP through the Golgi is a requisite 
for formation of the J3-amyloid peptides (Haass et al., 1993; 
Busciglio et al., 1993). Monensin, an ionophore that neu- 
tralizes acidic intracellular compartments and promotes 
the swelling of the Golgi, especially the trans-Golgi net- 
work, also inhibits J3-amyloid formation. Other acidotrophic 
agents, such as chloroquine and NH4CI, have partial to 
full inhibitory effects on the production of these peptides 
(Shoji et al., 1992; Haass et al., 1993; Busciglio et al., 
1993), also indicating that a mildly acidic compartment 
such as the distal Golgi complex or early endosome is 
involved. These same cellular compartments have been 
shown to be sites of proteolytic leavage leading to ~APP 
secretion (Kuentzel et al., 1993; Sambamurti et al., 1992; 
De Strooper et al., 1993). Hence, 3 kDa precursor frag- 
ments derived from 13APP secretion would be present in 
the same cellular compartment(s) that harbor the 4 kDa 
peptide precursor fragments. The trans-Golgi network 
and/or post-Golgi compartment have been identified as 
the primary site(s) of ~APP secretory cleavage (Kuentzel 
et al., 1993; Sambamurti et al., 1992; De Strooper et al., 
1993). J3APP secretory cleavage on the cell surface, a mi- 
nor cleavage site (Kuentzel et al., 1993), would also bring 
carboxy-terminal remnants into an endosomal compart- 
ment through protein internalization. Thus, while both 
amyloidogenic and nonamyloidogenic arboxy-terminal 
6APP fragments may reflect different initial processing 
events, it appears that these fragments are ultimately pro- 
cessed together to yield both the 3 and 4 kDa peptides. 
We found that MDL 28170 inhibitor treatment results in 
the accumulation of ~APP carboxy-terminal precursors in 
a subcellular compartment hat can degrade these frag- 
ments to other than ~-amyloid peptide products. This ca- 
tabolism is insensitive to leupeptin and E64 treatment, 
precluding the lysosome as the responsible subcellular 
site. Similarly, brefeldin A did not perturb the degradation 
of the preamyloid fragments, thereby excluding the endo- 
plasmic reticulum and the Klausner degradative pathway 
(Lippincott-Schwartz et al., 1988) as a potential site of ca- 
tabolism. The acidotropic agents, chloroquine and NH4CI, 
retarded the degradation of these fragments, indicating 
that a weakly acidic compartment is involved. Monensin, 
which can neutralize acidic compartments but which also 
disrupts distal Golgi cisternae, completely blocked degra- 
dation. Monensin was also found to disrupt the compart- 
ment and/or proteinase activity responsible for producing 
the cleavage that forms the carboxyl termini of the 13-amyloid 
peptides. In addition, using reduced temperature to block 
intracellular ~APP transport indicated that a post-Golgi 
compartment is responsible for the carboxy-terminal pro- 
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cess ing of J3-amyloid. There fore ,  the interpretat ion most  
compat ib le  with these data, as well  as those  def in ing 
~-amyloid pept ide format ion,  points to an ear ly  endosome 
as the probab le  site of 13APP catabol ism and 15-amyloid 
pept ide product ion.  
Lastly, it is important  to underscore  the observat ion  that 
susta ined inhibit ion of 13-amyloid format ion leads to an al- 
ternate  means  of  degradat ion  of  amylo idogen ic  precursor  
f ragments .  Fur thermore,  we  f ind that 13APP b iosynthes is  
and secret ion are unaf fected by t reatment  with the MDL 
inhibitor (unpubl i shed data). These  results suggest  that 
I~-amyloid is fo rmed as a nonob l igatory  degradat ive  by- 
product  from the catabol ism of  mature 13APP. More  im- 
portantly,  these  data  have posit ive impl icat ions for the po- 
tential  t reatment  of A lzheimer 's  d isease.  
Experimental Procedures 
Cell Culture, Radiolabeling, and Drug Treatment 
The CP-6 cell line was established by transfecting the human cDNA 
encoding the 695 amino acid isoform of 13APP, driven by the human 
13-actin promoter (Leavitt et al., 1984), into CHO cells using calcium 
phosphate according to standard procedures. Individual transfectants 
were isolated, subcloned, and characterized for expression of exoge- 
nous 13APP by Western blotting and immunoprecipitation procedures. 
CP-6 cells were propagated in a 1:1 mixture of Dulbecco's minimum 
essential medium and Coon's F12 medium with 10% fetal bovine se- 
rum in 10 cm dishes ( -  1 x 106 cells per dish). To metabolically radiola- 
bel protein with [35S]methionine/cysteine (Translabel, iCN), CP-6 cell 
monolayers were washed three times with saline and placed in serum-, 
methionine-, and cysteine-free medium for 30 min, after which time 
167 pCi/ml [~S]methionine/cysteine was added. Culture dishes were 
radiolabeled for various times depending on the experimental design. 
For pulse-chase experiments, cultures were labeled for 60 min, and 
cell monolayers were washed, placed in fresh media lacking isotope 
(chase), and incubated for varying lengths of time prior to harvesting. 
For both pulse-chase and continuous labeling experiments, it was de- 
termined that the low levels of methionine and cysteine were neither 
deleterious nor limiting to the cells during 24 hr. For radiosequencing 
experiments, CP-6 cells were incubated for 30 min in serum-free me- 
dium lacking the appropriate amino acid and then labeled with - 750 
llCi/ml [3H]alanine (Amersham) or -750 iiCi/ml [3H]phenylalanine 
(Amersham) in serum-free medium lacking alanine or phenylalanine, 
respectively, for 4 hr prior to harvesting. 
For experiments involving treatment with drugs, the following con- 
centrations were used: 200 ~M MDL 28170 inhibitor (Mehdi et al., 
1988; Mehdi, 1991), 200 I~M leupeptin (Boehringer Mannheim), 200 
I~M E64 (Boehringer Mannheim), 100 ~M chloroquine (Sigma), 30 mM 
NH4CI, 30 mM NH4-acetate, 30 mM methylamine, 10 p_M monensin 
(Calbiochem), and 10 p_M brefeldin A (Epicentre Technologies, Madi- 
son, Wl). Time of application of each drug was variable depending on 
the specific experiment. 
Inquiries regarding access to the MDL 28170 inhibitor should be 
made with the corresponding author. 
Antibodies 
A polyclonal antibody to a region in the I~APP cytoplasmic domain 
(position #704-730 of the I~APPTsl sequence) was prepared by re- 
peated immunization of rabbits with a conjugate of purified synthetic 
peptide and keyhole limpet hemocyanin. Polyclonal antisera to 13-amy- 
Ioid were raised in rabbits using a synthetic 13-amyloid 1-40 peptide 
purchased from Bachem (Torrance, CA). The peptide was conjugated 
to keyhole limpet hemocyanin. Both I~APP carboxy-terminal and 
13-amyloid antibodies were characterized for reactivity against their 
respective cognate immunogen in an enzyme-linked immunoadsor- 
bent sandwich assay, by immunoprecipitation of radiolabeled !SAPP 
fragments or ~-amyloid, and for the ability of their cog nate immunogen 
to block immunoprecipitation of the specific ~APP product. 
Sample Preparation, Immunoprecipitation, and Analysis 
Immunoprecipitation of conditioned medium (3 ml total) for ~-amyloid 
peptide detection was performed as follows. RIPA buffer (7 ml; 50 mM 
Tris-HCI [pH 7.5], 150 mM NaCI, 1% deoxycholate, 0.1% SDS, 1% 
Triton X-100) was added to clarified medium and precleared with 45 
I~1 of normal rabbit serum plus 100 I~1 of protein A-Sepharose (Phar- 
macia) by rocking at 23°C for 2.5 hr or 4°C overnight followed by 
centrifugation at low speed. Protein A-Sepharose (100 p.I) and p-amy- 
Ioid antiserum, BA2 (45 Id), were added to the low speed supernatant 
and incubated as above. The mixture was again centrifuged at low 
speed, and the pellet was washed twice with 50 mM Tris-HCi (pH 
7.5), 500 mM NaCI, 5 mM EDTA, 0.5% Nonidet P-40, twice with 50 
mM Tris-HCI (pH 7.5), 150 mM NaCI, 5 mM EDTA, 0.5% Noniclet 
P-40, and twice with 10 mM Tris-HCI (pH 7.5). The entire pellet was 
resuspended in SDS reducing sample buffer and loaded onto one lane 
of a 16.5% Tris-Tricine SDS-polyacrylamide gel (Zhong et al., 1994). 
For immunoprecipitation of ~APP carboxy-terminal fragments, cell ly- 
sates were prepared according to the method of Gabuzda et al. (1991). 
Each cell lysate, diluted to 5 ml with RIPA buffer, was precleared with 
normal rabbit serum and protein A-Sepharose as described above. 
~APP carboxy-terminal ntiserum, BC1 (30 p_l), and protein A-Sepha- 
rose (100 ~1) were added to the lysate mixture, after which the immuno- 
precipitation and gel electrophoresis teps followed the same proce- 
dures as described above for conditioned medium samples. All gels 
were developed using autoradiography. Film exposure times were 
- 4-6 days for I~-amyloid peptides and overnight for 13APP carboxy- 
terminal fragments, Densitometry was carried out using a Phosphorlm- 
ager (Molecular Dynamics). 
Amino Acid Sequence Analysis 
Carboxy-terminal fragments were prepared by immunoprecipitation 
and separated electrophoretically as described above. Protein frag- 
ments were transferred to polyvinylenedifluoride membranes, excised 
using [~S]methionine/cysteine-labeled r ference ~APP fragments run 
on an adjacent lane of the gel, and subjected to Edman degradation 
using an Applied Biosystems A77A protein sequenator (Foster City, 
CA) using the BLOTT-2 program according to the manufacturer's rec- 
ommendations. Each degradation cycle was collected, mixed with 
scintillation fluid, and counted in a Beckman LS 3801 scintillation 
counter. 
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